This EU Flu Day, Seqirus confirms record number of influenza vaccines delivered across Europe to meet increased demand
- Seqirus have delivered record numbers of influenza vaccines across
Europein time for this flu season, responding to increased demand during the coronavirus pandemic.
- The first annual EU Flu Day organised by Vaccines
Europelaunches today, 14 October, highlighting the importance of flu vaccination across Europe, particularly during the ongoing COVID-19 pandemic. Average influenza vaccination rates across Europeare currently at just over 40%, well short of the European target of 75%.1
The European Centre for Disease Prevention and Controlestimates that 15,000-70,000 people in Europedie from influenza-related complications each year and encourages annual vaccination as the most effective way to prevent influenza.2
Providing frontline partnership for an influenza season unlike any other
The first annual EU Flu Day was launched today,
The EU Flu Day campaign is spearheaded by Dolors Montserrat, a leading Member of the European Parliament, and supported by Vaccines
There will be additional pressure on health care systems due to the COVID-19 pandemic. Immunisation against seasonal influenza will be critical to protect health care resources from becoming overwhelmed by increased demand, following a potential second wave of coronavirus disease.
"The potential for COVID-19 to persist or resurge during the upcoming influenza season is generating significant demand for influenza vaccines," said Enric Canelles, Seqirus VP Commercial Operations, EMEA. "It is important to protect those most at risk from influenza because they are also the most vulnerable to COVID-19. As the only global vaccine company solely dedicated to the prevention of influenza, Seqirus is rising to the challenge by partnering with public health in efforts to protect the people and health systems of
As a global manufacturer, Seqirus provides vaccines against seasonal influenza for both the Northern and Southern Hemisphere countries, where the nature and pattern of virus circulation in one hemisphere can be instructive for prevention and control in another. This year, Seqirus partnered with the Australian Government to deliver a record number of flu vaccines, working closely with experts and health care professionals to navigate social distancing requirements and periods of lockdown. Seqirus has drawn on this experience from the Southern Hemisphere season, working closely with stakeholders, to inform the approach to the forthcoming influenza season in
"In Australia, we saw very strong demand for flu vaccines earlier than usual, with people recognising the particular importance of flu vaccination programs this season," said
Seqirus is part of
CSL (ASX:CSL) is a leading global biotechnology company with a portfolio of medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.
Today, CSL — including our two businesses, CSL Behring and Seqirus - provides health products to more than 70 countries and employs more than 27,000 people. Our proven combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live their lives. For more information about
+44 (0) 7920 500 496
1 Eurostat database. Available at https://appsso.eurostat.ec.europa.eu/nui/show.do?query=BOOKMARK_DS-372339_QID_-5F2F50B2_UID_-3F171EB0&layout=TIME,C,X,0;GEO,L,
2 ECDC. Factsheet about seasonal influenza. Available at https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet (accessed: 13 August 2020)
3 EURO WHO. Influenza - Estimating burden of disease. Available at https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza (accessed: